secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tenaya Therapeutics, Inc. (TNYA)
CIK:        0001858848
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0000950170-22-024496
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenaya Therapeutics Q3 net loss $30.7M; cash runway extended to mid-2024
------------------------------------------------------------------------

- Cash and investments $149.5M as of Sept 30; funds expected to support operations to mid-2024.
- R&D expenses $23.8M, G&A $7.5M; net loss $30.7M ($0.74 per share).
- Dosing started in Phase 1 trial for TN-301 (HDAC6 inhibitor for HFpEF); data expected in 2023.
- Plans to submit IND for TN-201 (MYBPC3 gene therapy for HCM) by year-end 2022; IND for TN-401 in 2023.
- USPTO granted patent for TN-201 covering AAV therapy with MYBPC3; patent for TN-301 HDAC6 inhibitor allowed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858848/000095017022024496/0000950170-22-024496-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858848/000095017022024496/tnya-20221110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024496

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer